General Information
Drug ID
DR00688
Drug Name
Gemifloxacin
Synonyms
7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; Factiv; Factiv (TN); Factive; Factive (TN); Gemifloxacin (INN); Gemifloxacin [INN]; Gemifloxacin mesilate; LB 20304; LB 20304a; LB-20304; SB 265805; SB-265805
Drug Type
Small molecular drug
Indication Bacterial infections [ICD11: 1A00-1H0Z] Approved [1]
Therapeutic Class
Antibiotics
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=9571107"></iframe>
3D MOL 2D MOL
Formula
C18H20FN5O4
Canonical SMILES
CON=C1CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F
InChI
InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+
InChIKey
ZRCVYEYHRGVLOC-HYARGMPZSA-N
CAS Number
CAS 175463-14-6
Pharmaceutical Properties Molecular Weight 389.387 Topological Polar Surface Area 121
Heavy Atom Count 28 Rotatable Bond Count 5
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 10
PubChem CID
9571107
PubChem SID
103165376 , 104064190 , 124766444 , 126665045 , 131302500 , 134338130 , 135029930 , 137267488 , 141952322 , 14878468 , 152047100 , 162263733 , 163384560 , 172861476 , 175438039 , 179150073 , 223664023 , 226504227 , 238411063 , 23996711 , 251890177 , 251963973 , 252358754 , 44709303 , 46507905 , 48395332 , 50070532 , 50071315 , 50123382 , 57372939 , 610685 , 79751939 , 85305864 , 85789646 , 91613407 , 96024705
ChEBI ID
CHEBI:101853
TTD Drug ID
D0VR7W
DT(s) Transporting This Drug MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [2]
References
1 Gemifloxacin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.